High Graphics | Low Graphics
Latest Headlines | Word Search
Comment
J&J comes riding to Elan’s rescue
Johnson & Johnson has today taken what looks like a $1.5bn gamble on experimental drug bapineuzumab and the rest of Elan’s Alzheimer’s pipeline. In a surprising announcement the US group revealed that...
2 Jul 2009
Discovery Labs finds disappointment at end of the journey Subscription Only
After more than five years, four complete response letters and multiple conversations with the FDA over the approvability of its treatment for respiratory distress syndrome (RDS) in premature babies, ...
2 Jul 2009
Acorda's licensing deal misses the M&A mark Subscription Only
As widely expected Acorda Therapeutics today pulled a non-US licensing deal with Biogen Idec for Fampridine SR, its drug to improve walking speed and ability in MS patients, out of the bag, and for a ...
1 Jul 2009
AMAG poised to shoot from the blocks following Feraheme approval Subscription Only
The decision might have come at the third attempt and one day late, but AMAG Pharmaceuticals will certainly not be complaining. The FDA yesterday not only handed the company the gift of approval for i...
1 Jul 2009
123
To help you keep up to date with our most recent comment and analysis you can add our RSS feed to your browser. With the RSS feed you will receive instant notification of the new content on our website. You will be able to see the headlines, a brief description of stories and link straight back to EP Vantage.com. What is this? View Archive
Showing headlines from the Past 7 Days
 Retrieving...
Analysis
Sanofi-Aventis scores important approval goal with Multaq Subscription Only
The FDA’s approval of Multaq, for atrial fibrillation, could not have come at a better time for Sanofi-Aventis, whose shares have come under pressure recently amid concerns over whether insulin produc...
2 Jul 2009
Generic players continue to impress in the first half
With so much talk of patent cliffs and biosimilar regulatory pathways, 2009 is shaping up to be a boom time for investors in generic companies, a half-yearly analysis of stock performance by EP Vantag...
1 Jul 2009
Turning point for sales and R&D spend forecast for 2009 Subscription Only
In keeping with recently published IMS data predicting a decline in worldwide pharmaceutical sales this year, latest consensus forecasts from EvaluatePharma (World Preview 2014) also reveals that 2009...
30 Jun 2009
Biocon signs latest in string of biosimilar deals Subscription Only
As US lawmakers slowly move towards finalising the framework for approval of biosimilars, deals in the commercial sector are gathering pace. Yesterday, Mylan and India’s Biocon announced a tie up to d...
30 Jun 2009
12
To help you keep up to date with our most recent comment and analysis you can add our RSS feed to your browser. With the RSS feed you will receive instant notification of the new content on our website. You will be able to see the headlines, a brief description of stories and link straight back to EP Vantage.com. What is this? View Archive
Showing headlines from the Past 7 Days
 Retrieving...

Related Links

Registered Users

Subscribe Now

Word Search

Enter your free-text query in the box below